The effect of implantable cardioverter-defibrillator in patients with diabetes and non-ischaemic systolic heart failure

Rasmus Rørth, Jens Jakob Thune, Jens C Nielsen, Jens Haarbo, Lars Videbæk, Eva Korup, James Signorovitch, Niels E Bruun, Hans Eiskjær, Christian Hassager, Jesper Hastrup Svendsen, Dan E Høfsten, Christian Torp-Pedersen, Steen Pehrson, Lars Køber, Søren L Kristensen

Publikation: Bidrag til tidsskriftArtikelForskningpeer review

Abstract

AIMS: Implantable cardioverter-defibrillator (ICD) implantation reduce the risk of sudden cardiac death, but not all-cause death in patients with non-ischaemic systolic heart failure (HF). Whether co-existence of diabetes affects ICD treatment effects is unclear.

METHODS AND RESULTS: We examined the effect of ICD implantation on risk of all-cause death, cardiovascular death, and sudden cardiac death (SCD) according to diabetes status at baseline in the Danish Study to Assess the Efficacy of ICDs in Patients with Non-ischaemic Systolic Heart Failure on Mortality (DANISH) trial. Outcomes were analysed by use of cumulative incidence curves and Cox regressions models. Of the 1116 patients enrolled, 211 (19%) had diabetes at baseline. Patients with diabetes were more obese, had worse kidney function and more were in New York Heart Association Class III/IV. The risk of device infections and other complications in the ICD group was similar among patients with and without diabetes (6.1% vs. 4.6% P?=?0.54). Irrespective of treatment group, diabetes was associated with higher risk of all-cause death, cardiovascular death, and SCD. The treatment effect of ICD in patients with diabetes vs. patients without diabetes was hazard ratio (HR)?=?0.92 (0.57-1.50) vs. HR?=?0.85 (0.63-1.13); Pinteraction?=?0.60 for all-cause mortality, HR?=?0.99 (0.58-1.70) vs. HR?=?0.70 (0.48-1.01); Pinteraction?=?0.25 for cardiovascular death, and HR?=?0.81 (0.35-1.88) vs. HR?=?0.40 (0.22-0.76); Pinteraction?=?0.16 for sudden cardiac death.

CONCLUSION: Among patients with non-ischaemic systolic HF, diabetes was associated with higher incidence of all-cause mortality, primarily driven by cardiovascular mortality including SCD. Treatment effect of ICD therapy was not significantly modified by diabetes which might be due to lack of power.

OriginalsprogEngelsk
TidsskriftEuropace
DOI
StatusUdgivet - 1 aug. 2019

Bibliografisk note

Published on behalf of the European Society of Cardiology. All rights reserved. � The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.

Fingeraftryk

Udforsk hvilke forskningsemner 'The effect of implantable cardioverter-defibrillator in patients with diabetes and non-ischaemic systolic heart failure' indeholder.

Citationsformater